Most importantly, new pharmacological targets that block the inhibition of IFN-γ production would potentially reduce the number of individuals evolving to active disease or at least the frequency of lepromatous leprosy that significantly impacts leprosy transmission. The gene discussed is IFNG; the disease is leprosy.